What You Should Know:
– Adaptive Biotechnologies Corporation and Flatiron Health today announced the integration of Adaptive’s clonoSEQ® test for measurable residual disease (MRD) assessment in lymphoid malignancies into OncoEMR®, Flatiron’s cloud-based Electronic Medical Record (EMR) platform.
– The integration aims to simplify and accelerate access to MRD testing for over 4,500 clinicians across Flatiron’s network of 1,000 community-based cancer care locations in the U.S..
Enhancing Precision Oncology in Community Care
MRD refers to the number of cancer cells that may remain in a patient’s body during and after treatment, which can eventually lead to disease recurrence. The status of MRD is a strong predictor of outcomes in blood cancer patients, and routine testing offers a personalized way to track an individual’s response to treatment and inform clinical decision-making for optimized care.
The integration, effective July 1, 2025, for all OncoEMR’s Molecular Profiling Integration (MPI) users , enables providers to order and review clonoSEQ MRD testing results directly within the EMR. This streamlined workflow is expected to provide more efficient testing and increase real-time insights into a patient’s disease status.
Beyond the Flatiron network, clonoSEQ will continue to be accessible to providers through a rapidly expanding number of other EMR integrations and via Adaptive’s online diagnostic portal.
We are thrilled to add clonoSEQ as the latest precision oncology test to be integrated within OncoEMR’s Molecular Profiling Integration (MPI) platform,” said Quincy Weatherspoon, VP & GM, Flatiron Point of Care Solutions at Flatiron Health. “MPI has demonstrated benefits for providers and for labs, as it facilitates rapid and accurate exchange of orders and results while also ensuring that every step in the testing workflow is interconnected and transparent. Given clonoSEQ’s unique value proposition for blood cancer patients, we are proud to partner with Adaptive to advance the test’s role in community-based care.”
